{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:33:56Z","timestamp":1764401636098},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.11.046","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T18:16:00Z","timestamp":1418148960000},"page":"708-712","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012"],"prefix":"10.1016","volume":"33","author":[{"given":"Ingrid B.","family":"Rabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2014.11.046_bib0005","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.vaccine.2014.11.046_bib0010","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973\u20132008","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med"},{"issue":"RR-1","key":"10.1016\/j.vaccine.2014.11.046_bib0015","first-page":"1","article-title":"Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2014.11.046_bib0020","series-title":"Ixiaro \u2013 summary basis for regulatory action","author":"United States Food and Drug Administration","year":"2009"},{"issue":"20","key":"10.1016\/j.vaccine.2014.11.046_bib0025","first-page":"661","article-title":"Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"issue":"1","key":"10.1016\/j.vaccine.2014.11.046_bib0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2010","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2014.11.046_bib0035","first-page":"664","article-title":"Update on Japanese encephalitis vaccine for children: United States, May 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"issue":"4","key":"10.1016\/j.vaccine.2014.11.046_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"issue":"9602","key":"10.1016\/j.vaccine.2014.11.046_bib0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.vaccine.2014.11.046_bib0050","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"issue":"5-6","key":"10.1016\/j.vaccine.2014.11.046_bib0055","first-page":"575","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"26","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.11.046_bib0060","series-title":"Code of Federal Regulations Title 21, Sec. 600.80 Postmarketing reporting of adverse experiences","author":"United States Food and Drug Administration","year":"2013"},{"issue":"31","key":"10.1016\/j.vaccine.2014.11.046_bib0065","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2014.11.046_bib0070","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2007.04.058","article-title":"Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data","volume":"25","author":"Tapiainen","year":"2007","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2014.11.046_bib0075","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.11.046_bib0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain\u2013Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2014.11.046_bib0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2014.11.046_bib0090","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/S0264-410X(00)00111-0","article-title":"Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group","volume":"18","author":"Takahashi","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.046_bib0095","unstructured":"Food and Drug Administration Product approval information [package insert]. ACAM2000 (Smallpox (Vaccinia) Vaccine, Live). Sanofi Pasteur Biologics Co. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142572.pdf [accessed 07.1114]"},{"issue":"2","key":"10.1016\/j.vaccine.2014.11.046_bib0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(96)00170-3","article-title":"Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines","volume":"15","author":"Sakaguchi","year":"1997","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2014.11.046_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jtm.12001","article-title":"Allergy to IXIARO and BIKEN Japanese encephalitis vaccines","volume":"20","author":"McCallum","year":"2013","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2014.11.046_bib0110","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine Ixiaro","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1401603X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1401603X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T23:52:48Z","timestamp":1538005968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1401603X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X1401603X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}